BioNexus Gene Lab Corp Common stock (BGLC) Financials
$1.44
As on 15-Sep-2026 16:00EDT
Market cap
$5 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
3.13
|
7.42
|
9.51
|
9.77
|
10.93
|
13.36
|
|||||
|
Cost of Revenue
|
2.76
|
6.34
|
8.22
|
8.44
|
9.67
|
11.17
|
|||||
|
Gross Profit
|
0.36
|
1.09
|
1.29
|
1.33
|
1.26
|
2.19
|
|||||
|
Operating Expenses
|
3.44
|
4.24
|
2.86
|
3.92
|
1.55
|
1.14
|
|||||
|
Operating Profit (EBIT)
|
-2.59
|
-3.16
|
-1.57
|
-2.59
|
-0.29
|
1.06
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
--
|
-0.23
|
|||||
|
Profit before Tax
|
-2.58
|
-2.98
|
-1.59
|
-2.61
|
-0.30
|
1.04
|
|||||
|
Provision for Tax
|
--
|
--
|
0.00
|
0.02
|
0.05
|
0.29
|
|||||
|
Profit after Tax (Net Income)
|
-2.58
|
-2.98
|
-1.60
|
-2.63
|
-0.36
|
0.75
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
--
|
--
|
--
|
--
|
--
|
0.75
|
Liabilities ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
7.78
|
8.61
|
8.32
|
9.66
|
6.67
|
7.18
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
0.14
|
0.12
|
0.16
|
0.11
|
0.07
|
0.07
|
|||||
|
Current Liabilities
|
0.81
|
0.52
|
1.95
|
1.63
|
2.00
|
2.33
|
|||||
|
Total Liabilities
|
9.54
|
9.25
|
10.43
|
11.40
|
8.74
|
9.57
|
Assets ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
3.78
|
3.80
|
3.00
|
3.35
|
2.72
|
2.49
|
|||||
|
Current Assets
|
4.94
|
5.45
|
7.43
|
8.05
|
6.02
|
7.08
|
|||||
|
Total Assets
|
9.54
|
9.25
|
10.43
|
11.40
|
8.74
|
9.57
|
|||||
|
Total Debt*
|
0.20
|
0.18
|
0.21
|
0.15
|
0.06
|
0.08
|
|||||
|
Net Current Assets
|
4.13
|
4.93
|
5.48
|
6.42
|
4.02
|
4.82
|
Cashflow ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
-1.84
|
-2.23
|
-1.76
|
0.54
|
0.01
|
|||||
|
Cash Flow from Investing Activities
|
--
|
0.94
|
0.42
|
-1.86
|
-0.45
|
-0.49
|
|||||
|
Cash from Financing Activities
|
--
|
0.30
|
0.14
|
6.27
|
0.12
|
-0.03
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
--
|
-0.51
|
Financials Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-1.17
|
-1.23
|
-0.89
|
-1.49
|
-0.02
|
0.00
|
|||||
|
Cash EPS ($)
|
--
|
-1.17
|
-0.80
|
-1.43
|
-0.02
|
0.01
|
|||||
|
Adjusted Book Value ($)
|
--
|
3.56
|
4.63
|
5.47
|
0.46
|
0.04
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
-0.76
|
-1.24
|
-1.00
|
0.04
|
0.00
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
-0.78
|
-1.37
|
-1.08
|
0.03
|
0.00
|
Profitability Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-34.46
|
-17.43
|
-31.82
|
-5.09
|
10.70
|
|||||
|
ROE (%)
|
-31.42
|
-35.24
|
-17.78
|
-32.21
|
-5.14
|
10.86
|
|||||
|
ROA (%)
|
-24.86
|
-30.32
|
-14.64
|
-26.11
|
-3.89
|
7.63
|
|||||
|
EBIT Margin (%)
|
-39.96
|
-39.93
|
-16.55
|
-26.54
|
-2.66
|
7.90
|
|||||
|
Net Margin (%)
|
-82.36
|
-40.20
|
-16.81
|
-26.91
|
-3.26
|
5.72
|
|||||
|
Cash Profit Margin (%)
|
0.00
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-67.27
|
-0.22
|
-0.03
|
-0.11
|
-0.18
|
0.17
|
|||||
|
EBIT Growth (%)
|
50.73
|
-88.41
|
39.32
|
-790.72
|
-127.58
|
-17.11
|
|||||
|
Net Profit Growth (%)
|
12.21
|
-86.73
|
39.20
|
-638.57
|
-147.36
|
-31.31
|
|||||
|
EPS Growth (%)
|
28.54
|
-0.39
|
0.40
|
-59.52
|
-6.60
|
-1.00
|
|||||
|
Book Value Growth (%)
|
-23.14
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
-3.20
|
-0.31
|
-0.36
|
-38.63
|
485.24
|
|||||
|
Price / Book Value
|
0.56
|
1.11
|
0.06
|
0.10
|
2.06
|
50.79
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
629.53
|
-2.03
|
4.55
|
3.28
|
-54.82
|
310.21
|
|||||
|
Close Price ($)
|
1.95
|
3.95
|
2.80
|
5.30
|
9.50
|
21.30
|
|||||
|
High Price ($)
|
15.60
|
15.60
|
33.90
|
94.90
|
22.30
|
26.90
|
|||||
|
Low Price ($)
|
1.07
|
2.01
|
2.11
|
0.80
|
1.60
|
7.00
|
|||||
|
Market Cap ($ Cr)
|
4.72
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
--
|
0.02
|
0.03
|
0.02
|
0.01
|
0.01
|
|||||
|
Short term debt to equity ratio
|
0.01
|
0.01
|
0.01
|
0.00
|
0.00
|
0.01
|
|||||
|
Current Ratio
|
6.08
|
10.46
|
3.81
|
4.93
|
3.00
|
3.04
|
|||||
|
Quick Ratio
|
5.28
|
9.16
|
3.10
|
4.24
|
2.52
|
2.39
|
|||||
|
Interest Coverage
|
-151.43
|
-151.73
|
-74.42
|
-186.20
|
-23.33
|
81.39
|
Operating Efficiency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
5.94
|
8.74
|
16.62
|
8.77
|
26.53
|
25.12
|
|||||
|
Asset Turnover
|
0.30
|
0.75
|
0.87
|
0.97
|
1.19
|
1.36
|
|||||
|
Receivable days
|
--
|
54.83
|
46.81
|
70.22
|
104.55
|
100.53
|
|||||
|
Inventory Days
|
--
|
59.50
|
56.12
|
45.77
|
47.21
|
44.12
|
|||||
|
Payable days
|
--
|
43.37
|
64.54
|
70.60
|
73.15
|
84.75
|
|||||
|
Cash Conversion Cycle
|
--
|
70.95
|
38.38
|
45.40
|
78.61
|
59.90
|